补充剂在耐治疗的直肠癌中增加,并调节放射电阻
Rebecca M O'Brien1, Sebastian Meltzer2, Croí E Buckley3
1Department of Surgery, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland; Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland; Trinity St. James's Cancer Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.
补体系统,特别是C3,驱动对直肠癌治疗的耐药性. 抑制C3增强了辐射敏感性和改善了结果,确定补充剂作为治疗目标和生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 新辅助化学辐射疗法 (neo-CRT) 耐药性是局部晚期直肠癌治疗的一个主要挑战.
- 补充系统越来越多地与抗癌疗法耐药性有关.
- 需要新的治疗标和生物标志物来预测和克服新型CRT耐药性.
研究的目的:
- 调查补充系统在直肠癌放射电阻中的作用.
- 确定补充成分作为新CRT反应和患者存活的潜在生物标志物.
主要方法:
- 在耐辐射直肠癌细胞中评估了补充因子表达 (C3,C5) 和阿纳菲拉托克素产生 (C3a,C5a).
- 调节C3表达 (过度表达和抑制) 以评估其对放射反应的影响.
- 分析了人类直肠瘤组织和治疗前患者血清中的补充成分表达.
- 与新CRT反应和患者存活率相关的补充水平.
主要成果:
- 在耐辐射直肠癌细胞中观察到C3,C5,C3a和C5a的表达增加.
- 过度表达C3增强了放射电阻,而C3抑制显著增加了对辐射的敏感性.
- 抑制C3导致DNA损伤增加,并转向放射敏感细胞周期表型.
- 在人类直肠瘤中发现C3,C5和CFB表达的升高.
- 患者血清中较高的C3a和C5b-9治疗前水平与新型CRT反应和存活率差相关.
结论:
- 补体系统,特别是C3,在直肠癌中介导放射电阻方面发挥着重要作用.
- 抑制C3代表了一种有前途的策略,用于增强直肠癌治疗中的放射敏感性.
- 补充成分 (C3,C5,C3a,C5b-9) 是预测新CRT反应和患者结果的潜在生物标志物.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
